Chain Drug Review - Boehringer to buy Zantac
Friday, December 26th, 2008 RIDGEFIELD, Conn. — Boehringer Ingelheim Pharmaceuticals Inc. is buying the Zantac brand from Johnson & Johnson for $505.5 million.
Sale of the nonprescription heartburn drug is contingent on J&J completing its planned acquisition of the consumer health busin…
